Please login to the form below

Not currently logged in
Email:
Password:

FDA approves once-daily HIV treatment Complera

The FDA approves Johnson&Johnson/Gilead’s once daily, single tablet regime HIV-1 treatment, Complera

The US Food and Drug Administration (FDA) has approved Complera, a once-daily HIV treatment.

Complera is for the treatment of HIV-1 infection in treatment-naive adults, and works through combining Johnson & Johnson and Tibotec's Edurant (rilpivirine) and Gilead's Truvada (tenofovir/emtricitabine).

FDA approval was granted due to data gained from the late-stage ECHO and THRIVE studies. A bioequivalence study demonstrated that when compared to tenofovir and emtricitabine and rilpivirine, Complera achieved the same levels of medication in the blood.

Complera is expected to generate around $567m in revenue in 2013 according to Lazard Capital Markets analyst Joel Sendek, who referred to the drug as a “catalyst”.

Complera is the “second complete antiretroviral treatment for HIV-1”, that is available in a single tablet regimen.

11th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics